The S&P 500 ended 1.01% up today, after yesterday’s tumble.
This confirms what we told you yesterday – that the Wuhan virus is not a reason to panic sell your stocks.
We’ll continue to monitor the situation closely… and report back to you if that position changes.
5G… self-driving cars… augmented reality… and quantum computing are all breakthrough new technologies our tech expert, Jeff Brown, has on his radar.
But Jeff has scored the biggest wins in companies behind breakthroughs in CRISPR gene editing.
As we’ve been showing you, it allows doctors to “cut” and “paste” parts of your DNA code.
This is giving us godlike powers over our bodies. And for that reason, Jeff has dubbed this technology the “God Key.”
Last year, he gave his readers the chance to make gains of 332% and 432% on two leading gene-editing stocks.
And he believes these gains are just getting started.
That’s why, last week, I caught up with Jeff for a deep dive on the latest developments in CRISPR gene editing for members of our Legacy Inner Circle advisory. (Paid-up members can catch up in full here.)
And as you’ll see in the excerpt below, the pace of innovation is about to accelerate. That’s because gene-editing companies are starting to harness the power of another tech megatrend on Jeff’s radar – artificial intelligence (AI).
Chris Lowe: You’ve been pounding the table on the opportunity in biotech. And you just held your first free training event of the year about how folks can maximize their profits in the biotech boom.
In particular, you’re bullish on CRISPR gene-editing stocks. What is CRISPR? And why are you so bullish on the companies pioneering this breakthrough new tech?
Jeff Brown: Gene editing removes “bugs” – or mutations – from our DNA. DNA is the unique code in nearly all of our cells that makes us who we are.
So far, the most advanced gene-editing platform is CRISPR. It’s like software programming for our DNA. It allows scientists to “cut” a genetic mutation out of our DNA code and replace it with a healthy, mutation-free version.
I’ve been writing about the advances in gene-editing tech since 2016. What makes this an even more profitable opportunity right now is that biotech companies are starting to harness the power of another tech megatrend – AI.
Chris: Why is that so important?
Jeff: Our DNA is a long string of code. That makes it perfect for AIs. They excel at pattern recognition. They can trawl through huge data sets looking for different pieces of code that relate to different illnesses.
Take pancreatic cancer. It kills about 400,000 people worldwide every year.
Imagine we have a large database of human genomes. Think of it as a “map” of millions of human genomes. Pattern-seeking AIs can analyze that data and spot genetic sequences that people who get pancreatic cancer have in common. This allows them to link those sequences with pancreatic cancer.
Once the AIs figure out which segment of folks’ genomes is causing the disease, humans can then make therapies that “cut” the faulty code and “paste” non-faulty code… and prevent the disease from developing.
Chris: You’ve spilled a lot of ink on two groundbreaking trials on patients with sickle cell disease and beta thalassemia. These are inherited blood diseases that can be fatal if left untreated. What other areas are biotech companies targeting with these bleeding-edge technologies?
Jeff: Many of them are focusing on preventing and treating cancer.
If we didn’t die from something else, we’d eventually die from cancer. As our cells get very old, they degrade. Eventually, they become cancerous.
But as I talked about earlier, there are certain genetic sequences that increase the likelihood of getting cancer. So it will be possible to eliminate the mutations that make certain types of cancer likely.
That’s on the preventative side. In addition to using genetic editing to correct a genetic mutation that may lead to cancer, we can also use it to treat cancer in a patient who already has it.
A new area of research emerged last year using CRISPR genetic editing on T cells. T cells are immune-system cells. Scientists remove T cells from your body… and edit them to explicitly attack and destroy cancerous tumors without attacking healthy cells. Then, they put the T cells back in your body.
Chris: Are there other diseases we’ll soon be able to cure using CRISPR technology and AI?
Jeff: One of the hottest areas of research right now is Alzheimer’s disease.
We know there are specific genetic mutations that increase the likelihood of a person getting Alzheimer’s. But researchers just discovered a unique case. It involves a different genetic mutation that may stop the symptoms of dementia – even if the patient has the high-risk genes associated with early-onset Alzheimer’s.
Researchers identified a woman in Colombia who was predisposed to developing Alzheimer’s in her 40s. But she went more than three decades without experiencing any symptoms. No dementia. No confusion. No memory loss. Nothing.
And it all came down to this rare genetic mutation that scientists were not aware of.
It’s hard to overstate how huge this is. About 44 million people have Alzheimer’s worldwide. And it’s debilitating. Sufferers typically need one to four family members to act as caregivers.
And the Alzheimer’s drug market is worth an estimated $2.9 billion. So apart from the good news story of combatting this crippling disease… it’s also a phenomenal investment opportunity.
Now that we know the exact gene and mutation that’s involved in preventing Alzheimer’s symptoms from showing up, doctors can target their research.
Then they can gear therapies toward this specific gene… and give others the “immunity” that this woman in Colombia showed.
Chris: I can tell from talking to you that you’re really excited about what’s ahead of us once we start to apply AIs to discovering new gene therapies.
Jeff: It’s one of the top profit themes I’m tracking. As a result of what’s going on, we’ll see more change in medicine in the next 10 years than we’ve seen in the last 50.
It will be difficult for us to get our heads around. But by following along with my research, you’ll have a better grip on this than most investors. And the profit opportunities are just going to get bigger as innovation moves at a faster and faster pace.
Chris: Thanks, Jeff.
Jeff: You’re welcome. Anytime.
Regards,
Chris Lowe
January 28, 2020
Delray Beach, Florida
P.S. As Jeff showed folks who tuned in for his “Timed Stocks Summit” on Wednesday, there’s a powerful trading strategy you can use to boost your returns in biotech.
He’s uncovered a small group of tech stocks that – thanks to a government mandate – have a preset “timer” attached to their share prices. Once this “timer” hits zero, a stock can climb hundreds of percent in days or even hours.
“Timed stocks” are publicly traded companies. You can buy them with a few clicks on your brokerage account. If that all sounds too good to be true, then I encourage you to watch Jeff’s presentation.
It’s been a huge hit with your fellow readers. So far, 71,041 have tuned in. And today is your last chance to join them. We’ll be taking the summit footage down at midnight tonight. So make sure to catch it before it’s taken down.
Like what you’re reading? Send your thoughts to feedback@legacyresearch.com.